You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Glioblastoma, Pembrolizumab, Immunotherapy, PD-1, PD-L1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Sep 25, 2023

Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Pembrolizumab in Combination with Plinabulin and Docetaxel
  • (no location specified)
Oct 28, 2022

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,

Withdrawn
  • Triple Negative Breast Cancer
  • +4 more
  • Aurora, Colorado
    University of Colorado Hospital
Dec 2, 2022

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 2, 2023

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
Oct 26, 2022

Glioblastoma Multiforme Trial in Los Angeles (drug, radiation, procedure)

Recruiting
  • Glioblastoma Multiforme
  • Los Angeles, California
    Cedars-Sinai Medical Center
Feb 24, 2022

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Non Small Cell Lung Cancer Trial in Pittsburgh (Fecal Microbiota Transplant (FMT), Pembrolizumab)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Dec 20, 2022

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma Trial in Nashville (DNA Vaccine, Human Papillomavirus

Not yet recruiting
  • Metastatic Oropharyngeal Carcinoma
  • Recurrent Oropharyngeal Carcinoma
  • DNA Vaccine
  • +6 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Mar 22, 2023

Efficacy of Immunotherapy in Hepatocellular Carcinoma

Recruiting
  • Hepatocellular Carcinoma
  • CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Oct 20, 2022

Contribution of Fractional Exhaled Nitric Oxide asPrognostic

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Measurement of FeNO
  • Dijon, France
    Chu Dijon Bourgogne
Aug 8, 2023

Small-cell Lung Cancer Trial in Shanghai (thoracic radiotherapy)

Recruiting
  • Small-cell Lung Cancer
  • thoracic radiotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
Sep 21, 2022

Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

Recruiting
  • SCLC,Extensive Stage
  • PD-(L)1 antibody immunotherapy
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
Jul 3, 2023

Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8 Trial in Atlanta

Recruiting
  • Metastatic Non-Small Lung Cell Cancer
  • +4 more
  • Atlanta, Georgia
    Winship Cancer Institute of Emory University
Oct 19, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023